Intellia jumps as FDA lifts clinical hold on nex-z for ATTR-CM
Source: SeekingAlpha
2026-03-02 16:10:43 ET
More on Intellia Therapeutics
- Intellia Therapeutics, Inc. (NTLA) Q4 2025 Earnings Call Transcript
- Intellia Therapeutics: 2 Major Catalysts Will Determine Stock's Trajectory In 2026
- Intellia Therapeutics: Maintaining A Sell Rating As Platform Risks Escalate
- Intellia outlines 2026 lonvo-z launch plans as FDA lifts clinical hold on MAGNITUDE-2
- Intellia Therapeutics GAAP EPS of -$0.83 beats by $0.12, revenue of $23.02M beats by $10.85M
Read the full article on Seeking Alpha
For further details see:
Intellia jumps as FDA lifts clinical hold on nex-z for ATTR-CM
Intellia Therapeutics Inc.
NASDAQ: NTLA
NTLA Trading
0.03% G/L:
$12.73 Last:
1,289,650 Volume:
$13.02 Open:
NTLA Latest News
March 03, 2026 07:30:00 am
Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026
March 02, 2026 07:30:00 am
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM
NTLA Stock Data
$1,420,074,893
112,239,198
1.45%
105
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
